October 2, 2020
Patient and nurse before scan

Screening and surveillance: catching cancer early

A screening study is one that tests new ways to find disease early; a surveillance study investigates methods to monitor an unusual finding – such as a cyst or mole – that may or may not turn into cancer. This issue explores several such trials in breast and pancreas cancers.
October 2, 2020
Patient and doctor before scan

Now Enrolling: The EA2185 trial is comparing two standard methods to follow patients with non-cancerous cysts in the pancreas

This trial compares two common surveillance methods for people with at least one non-cancerous cyst in the pancreas, to measure which one leads to better outcomes. The study may also uncover findings that could predict the behavior of these cysts.
October 2, 2020
Women laughing together

Ongoing Trial: In the TMIST mammography trial, nearly 20% of the volunteers are Black women, thanks to a successful recruitment strategy

The TMIST breast cancer screening trial continues to enroll women during the COVID-19 pandemic. This article describes ways trial leaders and clinical staff are making TMIST available to women in minority communities.
October 2, 2020

Trial Results: A 10-minute MRI proves useful in women with dense breasts at average risk of developing breast cancer

Dr. Christopher Comstock, a radiologist who specializes in breast cancer imaging, talks about the results of clinical trial EA1141 and how it will hopefully give far more women access to a powerful tool in the fight against breast cancer
October 2, 2020
Woman holding cloud on string in place of head

Trial Results: For women with breast cancer in the TAILORx trial, cognitive decline from chemo was early and abrupt but did not get worse over time. Cognition also declined in the group on hormone therapy alone.

Cognitive loss—or ‘brain fog’—involves memory problems, a lack of mental clarity, and difficulty keeping one’s focus. Cancer-related brain fog is common during treatment. This study dispels the idea that it is only from chemotherapy.
June 10, 2020
Valerie Guild headshot

Remembering Valerie Guild, a tireless advocate for patients with melanoma

Valerie Guild was Founder and President of the non-profit organization AIM at Melanoma, and served as a patient advocate on ECOG-ACRIN’s Melanoma Committee for over ten years.